Literature DB >> 9430233

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.

C A Chambers1, T J Sullivan, J P Allison.   

Abstract

CTLA-4-deficient animals develop a fatal lymphoproliferative disorder. The cellular mechanism(s) responsible for this phenotype have not been determined. Here, we show that there is a preferential expansion of CD4+ T cells in CTLA-4(-/-) mice, which results in a skewing of the CD4/CD8 T cell ratio. In vivo antibody depletion of CD8+ T cells from birth does not alter the onset or the severity of the CD28-dependent lymphoproliferative disorder. In contrast, CD4+ T cell depletion completely prevents all features characteristic of the lymphoproliferation observed in CTLA-4-deficient mice. These results demonstrate that CD4+ T cells initiate the phenotype in the CTLA-4(-/-) mice. Further, these results suggest that the role of CTLA-4 in peripheral CD4+ versus CD8+ T cell homeostasis is distinct.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430233     DOI: 10.1016/s1074-7613(00)80406-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  120 in total

Review 1.  Function and regulation of memory CD4 T cells.

Authors:  D P Metz; K Bottomly
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Differences in the regulation of CD4 and CD8 T-cell clones during immune responses.

Authors:  P C Beverley; M K Maini
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

Review 3.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 4.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

Review 5.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

6.  Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.

Authors:  Jillian H Hurst
Journal:  J Clin Invest       Date:  2015-09-08       Impact factor: 14.808

7.  Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.

Authors:  Yu Jin Lim; Jaemoon Koh; Kyubo Kim; Eui Kyu Chie; Sehui Kim; Kyoung Bun Lee; Jin-Young Jang; Sun Whe Kim; Do-Youn Oh; Yung-Jue Bang
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 8.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

10.  Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; William J Quinn; Michael P Cancro; Huaxin Gao; Chaim Putterman; Xiaoni Gao; Luminita Pricop; Michael N Koss
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.